A controlled trial of ondansetron in the pruritus of cholestasis

Alimentary Pharmacology and Therapeutics

Volumn 21, Issue 8, 2005, Pages 1041-1045

  O'Donohue, J W ^a,d   Pereira, S P ^a,b   Ashdown, T A C ^b   Haighj, C G ^c   Wilkinson, J R ^c   Williams, R ^a,b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ONDANSETRON; PLACEBO;

ADULT; AGED; ARTICLE; CHOLESTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMOEPIDERMAL JUNCTION; DOUBLE BLIND PROCEDURE; FEMALE; HEADACHE; HUMAN; LIVER DISEASE; MALE; NAUSEA; PIEZOELECTRICITY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SENSORY NERVE; SIDE EFFECT; VISUAL ANALOG SCALE;

EID: 17344364823     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02430.x     Document Type: Article

References (29)

1. Crowe J, Christensen E, Doniach D, Popper H, Tygstrup N, Williams R. Early features of primary biliary cirrhosis: an analysis of 85 patients. Am J Gastroenterol 1985; 80: 466-8.
2. Schoenfield LI, Christensen E, Doniach D, Popper H, Tygstrup N, Williams R. Bile acids in the skin of patients with pruritic hepatobiliary disease. Nature 1967; 213: 466-8.
3. Ghent CN, Bloomer JR, Klatskin G. Elevations in skin tissue levels of bile acids in human cholestasis: relation to serum levels and to pruritus. Gastroenterology 1977; 73: 1125-30.
4. Varadi DP. Pruritus induced by crude bile and purified bile acids. Experimental production of pruritus in human skin. Arch Dermatol 1974; 109: 678-81.
5. Walt RP. Effect of stanozolol on itching in primary biliary cirrhosis. Br Med J 1988; 290: 607.
6. Stander S, Steinhoff M, Schmelz M, Weisshaar E, Metze D, Luger T. Neurophysiology of pruritus: cutaneous elicitation of itch. Arch Dermatol 2003; 139: 1463-70.
7. Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. BMJ 1988; 297: 1501-4.
8. Bergasa NV, Alling DW, Talbot TL, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 1995; 123: 161-7.
9. Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol 1999; 41: 431-4.
10. Woolf GM, Reynolds TB. Failure of rifampin to relieve pruritus in chronic liver disease. J Clin Gastroenterol 1990; 12: 174-7.
11. Bachs L, Pares A, Elena M, Piera C, Rodes J. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992; 102: 2077-80.
12. Podesta A, Lopez P, Terg R, et al. Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci 1991; 36: 216-20.
13. Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988; 94: 488-93.
14. Bloomer JR, Boyer JL. Phenobarbital effects in cholestatic liver diseases. Ann Intern Med 1975; 82: 310-7.
15. Browning J, Combes B, Mayo MJ. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2003; 98: 2736-41.
16. Yosipovitch G, Greaves MW, Schmelz M. Itch. Lancet 2003; 361: 690-4.
17. Krajnik M, Zylicz Z. Understanding pruritus in systemic disease. J Pain Symptom Manage 2001; 21: 151-68.
18. Arthur RP, Shelley WB. The innervation of human epidermis. J Invest Dermatol 1959; 32: 397-411.
19. Mela M, Mancuso A, Burroughs AK. Review article: Pruritus in cholestatic and other liver diseases. Aliment Pharmacol Ther 2003; 17: 857-70.
20. Richardson BP. Serotonin and nociception. Ann N Y Acad Sci 1990; 600: 511-9; discussion 519-20.
21. Richardson BP, Engel G, Donatsch P, Stadier PA. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 1985; 316: 126-31.
22. Schworer H, Ramadori G. Improvement of cholestatic pruritus by ondansetron. Lancet 1993; 341: 1277.
23. Schworer H, Ramadori G. Treatment of pruritus: a new indication for serotonin type 3 receptor antagonists. Clin Investig 1993; 71: 659-62.
24. Raderer M, Muller C, Scheithauer W. Ondansetron for pruritus due to cholestasis. N Engl J Med 1994; 330: 1540.
25. Schworer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995; 61: 33-7.
26. Muller C, Pongratz S, Pidlich J, et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 1998; 10: 865-70.
27. Talbot TL, Schmitt JM, Bergasa NV, Jones EA, Walker EC. Application of piezo film technology for the quantitative assessment of pruritus. Biomed Instrum Technol 1991; 25: 400-3.
28. McCormack HM, Horne DJ, Sheather S. Clinical applications of visual analogue scales: a critical review. Psychol Med 1988; 18: 1007-19.
29. Blackwell CP, Harding SM. The clinical pharmacology of ondansetron. Eur J Cancer Clin Oncol 1989; 25 (Suppl. 1): 21-4.